Brexpiprazole (brand name Rexulti®) is a second-generation (“atypical”) antipsychotic first introduced in the US in 2015.
As of January 2024, it is available only as a brand name preparation (no generic), Rexulti®, that is manufactured by Otsuka Pharmaceutical Company Ltd and co-marketed with H. Lundbeck A/S.
On this page, we present basic information about this medication. Other articles on this website with more advanced information and tips related to this medication are linked to under Related Pages below.
Indications
1. “Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults”
2. “Treatment of schizophrenia in adults and pediatric patients ages 13 years and older”
3. “Treatment of agitation associated with dementia due to Alzheimer’s disease“. Limitations of Use: “REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease”.
Pharmacological effects
1. Partial agonist at the 5-HT1A, D2, and D3 receptors
2. Antagonist at 5-HT2A, 5-HT2B, 5-HT7, alpha-1 (subtypes A, B, and D), and alpha-2C receptors.
Dosing
1. For adjunctive treatment of major depressive disorder in adults
Starting dosage: 0.5 mg/day or 1 mg/day. Titrate up to the target dosage of 2 mg once daily
Recommended target dosage: 2 mg/day
Maximum dosage: 3 mg/day
2. For the treatment of schizophrenia
Starting dosage: 1 mg/day for four days. Then, 2 mg/day for three days Then 4 mg/day
Recommended target dosage: 2 mg to 4 mg once daily
3. For the treatment of agitation associated with dementia due to Alzheimer’s disease
Starting dosage: 0.5 mg/day during the first week
Titration: 1 mg/day during the second week
Target dosage (after 2 weeks): 2 mg/day
Maximum dosage: 3 mg/day, if needed based on response and side effects.
Potential side effects
Please see THIS PAGE for a handout listing both the common and less common side effects of this medication along with the percentages of patients who report them.
Dosage adjustments
Dose adjustments are recommended for patients who are:
1. Poor metabolizers on the CYP450 2D6 isoenzyme, or
2. Taking strong inducers/ inhibitors of CYP2D6 and/or CYP3A4.
Dosage forms and strengths
Rexulti® is available as tablets in the following dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg
Important! Please refer to the full Prescribing Information (see link below) before prescribing this medication.
Related Pages
Brexpiprazole (Rexulti®): Basic Prescribing Information
How are the pharmacological effects of brexpiprazole (Rexulti®) different?
Dopamine D2 receptor partial agonists: Receptor binding affinity and intrinsic activity
Potential side effects of brexpiprazole (Rexulti®)
Aripiprazole and brexpiprazole: Impulsive or compulsive urges and behavior
References
Prescribing information for brexpiprazole (Rexulti®)
Copyright © 2016 to 2026, Simple and Practical Medical Education, LLC. All rights reserved. The content on this website may not be reproduced in any form without express written permission.
Disclaimer: The material on this website is provided as general education for medical professionals. It is not intended for patients or other laypersons, nor is it a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified healthcare professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most up-to-date information.
What are your thoughts about choosing between cariprazine, aripiprazole and brexipiprazole?